Biotech News

Replimune to Present at Two Upcoming Investor Conferences

Replimune Group (REPL)Replimune Group2026-06-25 13:46 ESTConference / presentation

WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at

Open original release

Related news

REPLReplimune Group2026-06-25 13:46 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-25 13:46 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-25 13:46 EST

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

REPLReplimune Group2026-06-25 13:46 EST

Replimune Provides Update Following Type A Meeting with FDA

REPLReplimune Group2026-06-25 13:46 EST

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

REPLReplimune Group2026-06-25 13:46 EST

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

REPLReplimune Group2026-06-25 13:46 EST

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

REPLReplimune Group2026-06-25 13:46 EST

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

REPLReplimune Group2026-06-25 13:46 EST

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

REPLReplimune Group2026-06-25 13:46 EST

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Replimune Group

Replimune Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

REPLReplimune Group2026-06-26 10:40 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-26 10:40 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-06-26 10:40 EST

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

REPLReplimune Group2026-06-26 10:40 EST

Replimune Provides Update Following Type A Meeting with FDA

REPLReplimune Group2026-06-26 10:40 EST

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States